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Toll-like receptors (TLRs) and their downstream signaling pathways have been comprehen-
sively characterized in innate immunity. In addition to this function, these receptors have
also been suggested to be involved in the pathogenesis of many autoimmune diseases,
including rheumatoid arthritis (RA). Murine in vivo models and human in vitro tissue models
of RA have provided a wealth of information on the potential activity of TLRs and compo-
nents of the downstream signaling pathways. Whilst most early work investigated the cell
surface TLRs, more recently the focus has moved to the endosomal TLRs 3, 7, 8, and 9.
These receptors recognize self and foreign double-stranded RNA and single-stranded RNA
and DNA.The development of therapeutics to inhibit the endosomalTLRs or components of
their signaling cascades may represent a way to target inflammation upstream of cytokine
production.This may allow for greater specificity than existing therapies including cytokine
blockade. Here, we review the current information suggesting a role for the endosomal
TLRs in RA pathogenesis and the efforts to target these receptors therapeutically.
Keywords: rheumatoid arthritis, toll-like receptor, inflammation, autoimmunity, endosomal toll-like receptors,
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TOLL-LIKE RECEPTORS
Toll-like receptors (TLRs) are a family of evolutionarily conserved
pattern recognition receptors. There are 10 human TLRs, which
recognize pathogen associated molecular patterns from fungi, bac-
teria, and viruses, such as lipopolysaccharide (LPS), flagellin, and
dsRNA (1). In addition to pathogens, TLRs also respond to damage
associated molecular patterns (DAMPs), which are endogenous
molecules released at sites of inflammation and tissue damage;
examples include High Mobility Group Box 1 (HMGB-1) and
Tenascin C (2–4). Most TLRs are expressed at the cell surface
where they recognize mainly bacterial products, whereas TLRs 3,
7, 8, and 9 are localized to endosomal compartments and respond
to self and foreign nucleic acid structures. TLR3 recognizes dsRNA,
whilst TLR7 and TLR8 both respond to ssRNA (5). TLR9 recog-
nizes DNA, the binding event of which was believed to be sequence
specific, favoring CpG-rich DNA. However, recent evidence sug-
gests that DNA conformation is actually the key mediator of TLR9
activation, not the DNA sequence (6). Localization of these TLRs
Abbreviations: AC, apoptotic cell; CFA, complete Freund’s adjuvant; CIA, col-
lagen induced arthritis; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4;
DAMPs,damage associated molecular patterns; DC,dendritic cell; DMARD,disease-
modifying anti-rheumatic drug; HMGB-1, high mobility group box 1; hnRNP,
heterogenous nuclear ribonucleoprotein; IFN, interferon; IRF, interferon regulatory
factor; LL-37, cathelicidin family member human cationic antimicrobial peptide
LL-37; LPS, lipopolysaccharide; MAL, MyD88 adaptor like; MMP, matrix metallo-
protease; MTX, methotrexate; MyD88, myeloid differentiation primary response 88;
PIA, pristane induced arthritis; PTPN22, protein tyrosine phosphatase non-receptor
type 22; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor κB
ligand; RASF, rheumatoid arthritis synovial fibroblast; SLE, systemic lupus erythe-
matosus; TLR, toll-like receptor; TNF, tumor necrosis factor; TRAM, TIR domain
containing adaptor molecule 2; TRIF, TIR domain containing adaptor inducing
interferon-β; WT, wild type.
to the endosome likely represents a method of sequestering these
molecules from inadvertent activation by host nucleic acids.
Toll-like receptors form homo- or hetero-dimers upon acti-
vation and ligand binding. This dimerization event brings the
TIR domains into close proximity, allowing for the association
of adaptor molecules that trigger downstream signaling events
(Figure 1). There are four main adaptor proteins; Myeloid dif-
ferentiation primary response 88 (MyD88), MyD88 adaptor like
(MAL), TIR domain containing adaptor inducing interferon-β
(TRIF), and TIR domain containing adaptor molecule 2 (TRAM).
MyD88 is engaged by all of the TLRs except TLR3, MAL is used
by TLRs 2 and 4, TRIF by TLRs 3 and 4, and TRAM by TLR4. The
adaptor molecules trigger signaling via either the MyD88 depen-
dent pathway, which activates NF-κB, producing cytokines such
as tumor necrosis factor (TNF) and IL-1, or the MyD88 indepen-
dent pathway that leads to the activation of interferon regulatory
factor (IRF) family members and production of type-I interferons
(IFN) (7).
The TLRs have been extensively studied in both infectious
and chronic inflammatory diseases. In particular, their ability to
respond to endogenous ligands has made them attractive candi-
dates in the maintenance of inflammation in many autoimmune
diseases, including rheumatoid arthritis (RA).
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is an autoimmune disease affecting approx-
imately 1% of the worldwide population, characterized by the
infiltration and accumulation of activated immune cells in the syn-
ovial joints. Subsequent chronic production of pro-inflammatory
cytokines and matrix metalloproteases (MMPs) leads to destruc-
tion of the joint architecture, severe disability, and a reduced life
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FIGURE 1 | EndosomalTLR signaling to NF-κB and IRFs. Following
ligand binding, TLRs 7, 8, and 9 engage MyD88; for TLR8 this leads to
activation of NF-κB, whereas TLRs 7 and 9 engage IRAK1/4, TRAF3, and
TRAF6 to activate IRF family members. TLR3 uses the TLR adaptor TRIF,
which can induce NF-κB through the TRAF6 complex and can signal to
RIP-1 which, like the TRAF6 complex, can also activate the IKK-α,β,γ
complex. This results in dissociation of IκB from NF-κB, which can then
translocate to the nucleus and initiate gene transcription. Additionally, TRIF
can signal through TRAF3, TBK1, and IKK-i to initiate IRF-mediated
transcription.
expectancy due to co-morbid complications such as cardiovascular
disease (8).
Many different cell populations in the RA joint secrete cytokines
and other inflammatory mediators, which contribute to patho-
genesis. Macrophages are considered to be a major effector of
synovitis, secreting cytokines including TNF, IL-1, and IL-6 (9).
This inflammatory environment supports Th17 cell differentia-
tion and suppresses differentiation of regulatory T-lymphocytes,
thereby further promoting inflammation. In addition, RA synovial
fibroblasts (RASF) secrete IL-6 when stimulated by inflammatory
cytokines such as TNF and IL-17 (secreted by Th17 cells), thus
perpetuating the inflammatory cycle (10). RASFs can also express
receptor activator of nuclear factor κB ligand (RANKL), facili-
tating differentiation of monocytes/macrophages into osteoclasts,
thereby promoting pathological bone erosion (11). B-lymphocytes
and their progeny also contribute to the progression of RA patho-
genesis through pro-inflammatory cytokine production, in addi-
tion to generation of autoantibodies characteristic of disease.
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Although much is understood about the inflammatory environ-
ment in RA, the ligand(s) responsible for sustaining cytokine
production in this setting remains unknown.
Conventional treatment involves the use of disease-modifying
anti-rheumatic drugs (DMARDs), most commonly methotrexate
(MTX), as well as non-steroidal anti-inflammatory drugs, anti-
malarials, and corticosteroids (12). However, treatment of RA
has been greatly enhanced over the past decade by the develop-
ment of biological therapies targeting molecules implicated in
RA pathogenesis. The longest standing are those targeting TNF;
the anti-TNF antibodies infliximab, adalimumab, and golimumab,
the polyethylene glycol-linked mAb fragment certolizumab pegol,
and the soluble TNF receptor-2-IgG-Fc fusion protein etaner-
cept (13, 14). Additional targets of clinically approved biological
therapies include the IL-1 receptor (anakinra), the IL-6 receptor
(tocilizumab), CD20 on B-lymphocytes (rituximab), and cyto-
toxic T-lymphocyte-associated antigen 4 (CTLA-4) (abatacept).
Other agents in early-stage clinical development include the anti-
IL-17 antibodies secukinumab and ixekizumab and the IL-17
receptor-blocking antibody brodalumab (14, 15).
Tumor necrosis factor inhibitors remain the gold standard of
biological therapies for RA even though approximately 30% of
patients show no significant improvement (16). There is data sug-
gesting that the use of biologics early in the course of disease may
induce clinical remission in some patients (15, 17), although many
patients do not achieve permanent remission. Some patients also
become refractory to treatment with time, due to the production
of antibodies against anti-TNF biologicals (18); in this situation
tocilizumab has been shown to be a successful alternative (19).
Interestingly, some anti-TNF patients report no clinical
improvement in their symptoms but do show a decreased pro-
gression of joint damage radiographically (20). This may sug-
gest a different threshold for the inflammatory versus the bone
damage-activating effects of TNF. In agreement with this con-
cept, in the human TNF transgenic murine model of arthritis,
low-dose administration of adalimumab had no effect on syn-
ovial inflammation but significantly reduced bone erosions by
inhibiting osteoclastogenesis (21).
Biological therapies, although a clear improvement over
DMARDs, do not represent an ideal therapeutic. They require par-
enteral administration, either intravenously or by subcutaneous
injection and are expensive to manufacture with their cost severely
restricting use. Global suppression of cytokine function also holds
the potential for serious adverse effects such as bacterial infections,
invasive fungal infections, and in the case of anti-TNF reactivation
of latent tuberculosis (22). In an effort to address these limita-
tions, low molecular weight inhibitors are in development to target
intracellular signaling molecules and prevent cellular responses to
cytokines. Several small-molecule inhibitors of the Janus kinase
family are currently in clinical development for the treatment of
RA (23). Tofacitinib, an inhibitor of JAK3 and JAK1 and, to a lesser
extent, JAK2 has recently been approved for the treatment of adults
with active RA (24).
Small molecular weight inhibitors of inflammation are highly
desirable due to their low cost of production. However, targeting
downstream signaling molecules may prove to be troublesome
due to the ubiquitous nature of many of these molecules in
multiple signaling pathways. This has been a particular problem
for inhibitors of p38 mitogen-activated protein kinases, which are
too toxic for use in the treatment of chronic conditions such as RA
(25). To provide a more targeted approach for inhibiting inflam-
mation, the receptors and early signaling events responsible for
driving cytokine production need to be identified. Studies from
both human and murine models of arthritis have indicated that the
endosomal TLRs or their signaling pathways may offer potential
targets for the development of new therapeutics for RA.
EXPERIMENTAL ARTHRITIS MODELS
One of the most commonly used methods of experimental arthri-
tis is the murine collagen-induced arthritis (CIA) model. CIA has
been observed to have numerous similarities to RA including ero-
sive joint damage and production of circulating autoantibodies
targeting type-II collagen (26). Initial studies utilizing knockout
mice suggested roles for MyD88, TLR2, and TLR4 (27, 28). How-
ever, induction of CIA relies upon complete Freund’s adjuvant
(CFA), which contains TLR2, 4, and 9 ligands, making interpreta-
tion of these results difficult. In recent years, research has expanded
to the endosomal TLRs, with experiments being performed across
a variety of models, including serum transfer models and the rat
pristane-induced arthritis (PIA) model. These additional models
also share pathological features of RA but unlike the CIA model
they do not require CFA for disease induction.
In the rat PIA model, a role was proposed for TLR3 follow-
ing the observations that TLR3 was significantly up-regulated
in splenocytes following pristane injection and stimulation of
TLR3 with poly-I:C exacerbated disease. Furthermore, in the same
study, down-regulation of TLR3 with siRNA ameliorated disease,
pointing to a key role in disease progression (29). Similarly, up-
regulation of TLR3 has been observed in splenocytes from both
PIA and CIA rat models, where administration of MTX inhib-
ited both disease symptoms and the increase in TLR3 expression
(30). Interestingly, synovial fibroblasts from PIA susceptible Dark
Agouti rats show elevated levels of TLR3 following co-culture with
conditioned media of pristane-stimulated T-cells (31), suggesting
a system whereby immune-surveillant cells might prime synovio-
cytes toward TLR responses. Together, these data suggest that TLR3
may function in the maintenance of disease. However, a conflict-
ing picture has emerged in the mouse CIA and K/BxN serum
transfer models where activation of TLR3 suppressed arthritis,
signifying a regulatory role in controlling rather than promoting
inflammation (32).
More consistency has been observed across disease models
for TLR7. Induction of TLR7 tolerance by a short-course treat-
ment with a TLR7 agonist (1V136) at levels insufficient to induce
cytokine production ameliorated disease in the K/BxN serum
transfer model (33). However, additional cross tolerance of TLR2
and TLR9 was also observed, possibly due to activation of the
negative regulators IRAK-M (interleukin-1 receptor-associated
kinase-M) and SHIP-1 (Src homology 2 domain containing inos-
itol polyphosphate phosphatase), making it difficult to delineate
which TLR was responsible for the reduction in disease. Support-
ive of a pathological role for TLR7, we have demonstrated in the
murine CIA model that TLR7−/− mice show a reduction in clinical
score, paw swelling, and number of paws affected when compared
www.frontiersin.org January 2014 | Volume 5 | Article 1 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thwaites et al. Endosomal toll-like receptors in rheumatoid arthritis
to wild type (WT) mice. This effect was limited to the maintenance
of disease rather than the initial onset, as demonstrated by a similar
number of WT and TLR7−/− mice developing disease (34). Simi-
larly, intra-articular knockdown of TLR7 using lentiviral delivery
of TLR7 shRNA has been reported to decrease radiologic measures
of disease activity in the rat CIA model (35).
The involvement of TLR8 in these models and the subsequent
relevance of the data to human disease are less straightforward.
Although TLRs 7 and 8 both recognize ssRNA and are closely phy-
logenetically related, in the murine system, only TLR7 is capable
of activating downstream signaling in response to ssRNA, whereas
in human cells both receptors are functional (36). TLR8−/− mice
develop spontaneous autoimmunity, characterized by increased
serum levels of IgM, IgG2a, and autoantibodies against small
nuclear ribonucleoproteins and dsDNA. Dendritic cells (DCs)
from these mice had increased TLR7 levels and were hyper respon-
sive to TLR7 activation. Concomitant TLR7 and TLR8 knockout,
or individual TLR7 knockout mice did not exhibit this autoim-
mune phenotype, suggesting the potential for TLR8 to regulate
TLR7 signaling in mice (37).
Similar to TLR3, TLR9 may have an anti-inflammatory role
in arthritis. Numerous intracellular autoantigens, including self-
nucleic acids, displayed on the cell surface of apoptotic cells
(ACs) can activate an anti-inflammatory effect in vivo (38, 39).
In the CIA model, administering ACs was shown to induce an
anti-inflammatory effect dependent on the presence of TLR9, as
determined using TLR9−/− mice. In addition, this effect was abol-
ished following DNAse treatment of ACs prior to treatment of CIA
mice (39). Thus, TLR9 may function to induce tolerance and could
have an important role in the prevention of inflammation. Indeed,
TLR-induced type-I IFN has been suggested to be protective in a
murine serum transfer model of arthritis. Protein tyrosine phos-
phatase non-receptor type 22 (PTPN22),a gene associated with RA
susceptibility, has been shown to be required for IFN production
upon TLR3, 4, 7, and 9 stimulation (40). PTPN22 knockout mice
were observed to no longer exhibit disease suppression following
TLR ligation in this arthritis model (41). This finding suggests
that the type-I IFN response may explain the anti-inflammatory,
tolerogenic role of TLR9 signaling. Interestingly, an association has
been observed between RA susceptibility and a polymorphism in
IRF5; a transcription factor downstream of the endosomal TLRs,
involved in the production of IFN (42). However, the role of IFN
currently remains controversial; whilst administration of IFN-β
can ameliorate disease in the murine CIA model, a double-blind
clinical trial found no significant improvement between IFN-β
and placebo-treated groups (43, 44).
Conversely, inhibition of TLR9 with an immunoregulatory
DNA sequence has been reported to alleviate disease activity and
delay disease onset in the rat PIA model, indicating a potential
role for TLR9, and possibly DNA ligands, in the development
of disease (45). Indeed, DNAse-II deficient mice develop an RA-
like polyarthritis, however, this was not dependent on TLR9, as
arthritis was also observed in DNAse-II/TLR9 double knockout
mice, suggesting that other innate DNA sensors may be of more
importance (46).
Though the duality of the effects of TLR stimulation in RA
models may appear contradictory, these observations may in fact
provide insights into fundamental TLR biology. Under some con-
ditions, TLR signaling may be immunoregulatory, however in
the presence of elevated levels of DAMPs and accessory mole-
cules such as LL-37, this may lead to pathological inflammation
given a susceptible genetic background (47). Similar complex-
ity has been reported in murine models of the IFN-mediated
autoimmune disease, systemic lupus erythematosus (SLE). An
immunoregulatory role was attributed to TLR9 following knock-
out, despite its requirement for pathogenic anti-DNA autoanti-
body production (48). However, inhibition of TLR9 has indicated
a pro-inflammatory role in the production of IFN in response to
DNA containing immune complexes (49).
Despite the seemingly conflicting evidence for the involvement
of some of the endosomal TLRs in experimental arthritis mod-
els, overall it would appear that there may be a role for one or
more of these receptors in driving the disease process. In fact, we
have demonstrated that combined inhibition of these receptors
using an off target effect of some anti-depressant drugs, thera-
peutically reduced clinical score, paw swelling, and histological
joint damage in the murine CIA model (34, 50). Furthermore, it
has been reported that activation of TLR7 and TLR9 with het-
erogeneous nuclear ribonucleoprotein (hnRNP) antigens from
splenocytes of a PIA animal can be used to transfer disease to
another animal. Nuclease treatment of hnRNPs or treatment with
hnRNP-associated nucleic acids alone demonstrated that only
the nucleic acid components were required (51). Interestingly,
humoral and cellular autoimmunity to hnRNP-A2/B1 is present
in approximately 50% of RA patients, which may be linked with
the ability of hnRNPs to activate TLR7 and TLR9 (51).
ENDOSOMAL TLRs IN RA
The potential role of TLRs in RA has led to a number of genetic
studies, including a genome-wide association study examining
common TLR single nucleotide polymorphisms (SNP). How-
ever, no significant associations with RA susceptibility, severity,
or response to treatment have been identified (52–54). However,
some small studies have revealed possible associations with TLR
SNPs in distinct ethnic cohorts. The TLR9 SNP rs187084 allele
variant TT has been modestly associated with RA susceptibility
in a Turkish RA population, although it was not linked in studies
of Dutch or French cohorts (53–55). Interestingly, the TLR8 SNP
rs5741883 has been associated with rheumatoid factor autoan-
tibody positivity in one study of a European population (56).
Nonetheless, functional studies of the endosomal TLRs in human
samples have suggested the potential involvement of these recep-
tors and their signaling pathways in RA. Indeed, we previously
demonstrated a role for MyD88, the adaptor protein used by TLRs
7, 8, and 9, in the spontaneous release of cytokines and MMPs
from human RA synovial tissue cultures (57).
Many studies have examined the expression and function of
these receptors in synovial tissue cells from patients compared
with tissue from osteoarthritis (OA) patients or healthy controls
(HCs). TLRs 3, 7, 8, and 9 are all expressed in the RA synovium,
which is a mixed cell population (58–60), with levels of TLRs
3, 7, and 9 elevated in comparison to either OA or HC tissue,
particularly in RASFs, DCs, and macrophages (59–62). Stimula-
tion of RA synovial cells with ligands for TLR3 and TLR8 can
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induce production of cytokines and MMPs, indicating that these
TLRs are functional within RA joint tissue (58, 60). In fact, out
of a range of TLR ligands, TLR8 induced the biggest secretion
of TNF from RA synovial cultures (58). Interestingly, mimick-
ing the hypoxic conditions of the in situ joint has been shown
to exacerbate cytokine and MMP production following activa-
tion of TLR3 in RASFs (63). This elevated response to hypoxia
may support pathogenic angiogenesis in the synovium through
the ability of TLR3 to induce vascular endothelial growth factor
and IL-8 (64). Furthermore, TLR3 can also promote osteoclasto-
genesis both directly and indirectly via up-regulation of RANKL
on RASFs following activation (65).
For endosomal TLRs to be activated in the RA joint, suitable
ligands would need to be present. RA necrotic synovial fluid cells
have been shown to release RNA that can activate TLR3 on RASFs
(59). Additionally, DNA released from necrotic cells may induce
cytokine production in a TLR9-dependent manner (59, 62, 66).
Nucleic acids are readily degraded outside of the cell, however in
the RA joint they may be protected by other molecules. The catheli-
cidin family member human cationic antimicrobial peptide LL-37
is present in RA synovial fluid at levels greater than HCs and is
known to bind RNA, protecting it from degradation (47, 67). In
addition, LL-37 is known to perpetuate signaling through TLRs 3,
7, 8, and 9 (67–69).
Further support for a contribution of these TLRs to the per-
petuation of inflammation in RA comes from the antimalarial
drugs chloroquine, hydroxychloroquine, and quinacrine, which
have been used since 1950s to treat RA and SLE (70, 71). These
drugs act as antagonists of TLR9 and to a lesser extent,TLR3,TLR7,
and TLR8 (72, 73). The mechanism was suggested to be due to
the inhibition of endosomal acidification; however, more recently
antimalarials have been shown to interact directly with nucleic
acids, causing modifications which prevent their binding to the
endosomal TLRs (73). We found that, when added to human RA
synovial cultures, chloroquine suppressed spontaneous cytokine
production, indicating the possibility of nucleic acids driving
inflammation in these samples (58). In addition to these results,
the anti-depressant inhibitors of the endosomal TLRs that were
effective in the CIA model also suppressed spontaneous cytokine
production in human RA synovial membrane cultures (34, 50, 58).
Neither of these approaches represent a clinically useful therapy
for RA, due to the effective dose exceeding clinically safe levels.
However, these studies, as summarized in Table 1, do highlight a
possible role for endosomal TLRs in the maintenance of inflam-
mation, as well as demonstrating the potential to selectively target
these receptors for the effective treatment of RA.
TARGETING THE ENDOSOMAL TLRs THERAPEUTICALLY
There has been significant interest in the modulation of TLR func-
tion in disease. In particular, endosomal TLR antagonists are in
development as promising candidates for the treatment of sev-
eral autoimmune diseases. Indeed, some therapies already in the
clinic are suggested to mediate their effect through endosomal
TLR blockade. As already mentioned, antimalarials are used for
the treatment of RA, but at the doses given clinically they will
only deliver a moderate effect on disease and are thus usually
administered in combination with other therapies (75). This is
most likely due to the serum levels not reaching those required for
effective TLR inhibition. Similarly, the gold-containing complex,
auranofin, has also been suggested to moderate its’ anti-rheumatic
effect through blockade of TLR3-dependent TRIF signaling (76).
With the aim of designing more effective therapies specif-
ically targeting TLRs in autoimmunity, many small molecules
and immune response modifiers are under development. A small
molecular weight inhibitor, CPG-52364, was initially described
for the treatment of SLE, but may have therapeutic potential in
other autoimmune diseases such as RA and psoriasis. CPG-52364
inhibits signaling following stimulation of TLR7, 8, or 9 in human
PBMCs (77); CPG-52364 entered Phase I clinical development in
2007, however, the results of this trial are yet to be published.
Table 1 | Dual nature of endosomalTLR signaling in RA and disease models.
Immunoregulatory Immunostimulatory
TLR3 Activation of TLR3 in CIA and K/BxN serum
transfer models suppresses arthritis (32)
Activation of TLR3 exacerbates PIA. In agreement, knockdown of TLR3 ameliorated disease (29)
Stimulation of TLR3 induces angiogenic and osteoclastogenic factors in human RA synovial
fibroblasts (64, 65)
Hypoxia induces heightened responses from TLR3 in RASFs (63)
TLR7 TLR7 has been suggested to contribute to CIA pathology in established disease (34)
hnRNP can activate TLR7 and can transfer disease in the PIA model (51)
TLR7 tolerance induced by sub-optimal stimulation alleviates the K/BxN serum transfer model (33)
TLR8 TLR8 has a potential role in suppressing
TLR7 responses in murine models (37)
In human RA synovial cultures, stimulation of TLR8 results in the greatest cytokine production (58)
Inhibition of TLR8 inhibits spontaneous cytokine release in a human RA synovial tissue model
(58, 74)
TLR9 An anti-inflammatory response is induced
on exposure of TLR9 to apoptotic cells (55)
Inhibition of TLR9 alleviates rat PIA model (45)
hnRNP acts as a ligand for TLR9 and can transfer disease in the PIA model (51)
Seemingly contradictory findings regarding the roles of the endosomal TLRs in human RA tissue models and differing experimental arthritis models have been
identified.
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Other inhibitors have followed into the clinical trial arena.
Dynavax Technologies demonstrated, in both plasmacytoid DCs
from SLE patients and in two lupus-prone mouse strains, that
glucocorticoid resistance could be mediated through activation of
TLR7 and TLR9 (78). Glucocorticoids are frequently used for the
treatment of many autoimmune and inflammatory conditions,
including RA, but the high doses required for effective treat-
ment lead to significant side-effects and restrict use. Dynavax
Technologies in partnership with GlaxoSmithKline have conse-
quently developed DV1179, a bifunctional inhibitor of TLR7 and
TLR9, which has been shown to reverse glucocorticoid resistance
in both human cells and animal models of lupus. DV1179 was
well-tolerated in a Phase I clinical trial and subsequently, a proof
of mechanism clinical study was initiated in SLE patients in late
2011 (79).
Idera Pharmaceuticals has two lead candidates in development
for the treatment of autoimmune diseases; IMO-3100, an antag-
onist of TLRs 7 and 9 and IMO-8400, an antagonist of TLRs 7,
8, and 9. In preclinical models of autoimmune diseases including
CIA, lupus, and psoriasis, these TLR antagonists have been shown
to inhibit Th1, Th17, and inflammasome pathways and suppress
production of cytokines such as TNF, IL-12, IL-6, and IL-17 (80,
81). The results of a Phase II clinical trial were recently announced
for IMO-3100; Idera reported that clinical improvements observed
in psoriasis patients treated with IMO-3100 for 4 weeks correlated
with the proposed mechanism of action for TLR antagonism (80).
IMO-8400 entered a Phase I clinical trial in late 2012 to assess
safety in healthy subjects. VentiRx Pharmaceuticals is also devel-
oping a TLR8 specific antagonist for the treatment of autoimmune
diseases; VTX-763 is a preclinical lead which shows marked inhi-
bition of TLR8-induced NF-κB activation and TNF production
in vitro (74).
CONCLUSION
The advent of anti-TNF therapeutics for the treatment of RA has
not only resulted in greatly enhanced disease outcomes for many
patients but has also raised a number of new questions regard-
ing the production of TNF, and the role of the innate immune
system in RA pathogenesis. Activation of endosomal TLRs repre-
sents a potential mechanism, which may contribute to the cytokine
production characteristic of the RA synovium. Key roles have
been attributed to these receptors in both murine and human
models of disease. Accordingly, numerous early-stage therapeu-
tics targeting endosomal TLRs and their signaling networks are in
development. Concerns will always be raised over targeting mol-
ecules with key roles within the immune system. However, with a
diverse range of innate immune receptors able to detect viral and
bacterial pathogens, it may be possible to target the endosomal
TLRs without compromising innate immunity due to compen-
sation from the other cytosolic RNA and DNA receptors such
as RIG-I (retinoic acid inducible gene-I) and AIM2 (absent in
melanoma 2) (5). The desired therapy would provide a small mol-
ecular weight inhibitor to deliver ease of administration with a
lower production cost than current biological therapies. It is also
hoped that targeting upstream disease mechanisms may addition-
ally afford greater efficacy than global suppression of individual
cytokines.
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